Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2012 Primary endpoint amended as reported by ClinicalTrials.gov.